Clinical trial · Observational
Outcomes of Acute Myeloid Leukemia Patients
Outcomes of Acute Myeloid Leukemia Patients in Assiut University Hospital
NCT04392310CI-TRIAL-00045129unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
1. To assess overall survival of AML patient. 2. To measure rate of disease free survival. 3. rate of non relapse mortality. 4. rate of complete remission . 5. percentage of refractory disease. 6. percentage of relapsed disease.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Assessment of the overall survival of AML patients.
- timeFrame
- One year
- description
- Assessment of the overall survival of AML patients.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * AML patients, aged more than 18yrs and received chemotherapy (aggressive or palliative). Exclusion Criteria: * patients less than 18years old.
References
Publications (1)
- BACKGROUNDDe Kouchkovsky I, Abdul-Hay M. 'Acute myeloid leukemia: a comprehensive review and 2016 update'. Blood Cancer J. 2016 Jul 1;6(7):e441. doi: 10.1038/bcj.2016.50. PMID 27367478